Elevance Health, Inc. 8-K

What Happened Elevance Health, Inc. filed a Form 8-K (Regulation FD disclosure) on June 10, 2026 stating company officers will speak with investors and analysts this week and will reaffirm full‑year 2026 shareholders’ earnings guidance of at least $19.85 per diluted share. That figure includes about $6.90 per diluted share of net unfavorable items; excluding those, the company expects adjusted shareholders’ earnings of at least $26.75 per diluted share. Management also reaffirmed full‑year 2026 benefit expense ratio guidance of 90.2% ± 50 basis points. The company noted this guidance does not include any adjustment items beyond those reported in its Q1 2026 results.

Key Details

• Filing: Form 8‑K (Item 7.01, Regulation FD) filed June 10, 2026.
• Shareholders’ earnings guidance: ≥ $19.85 per diluted share for full‑year 2026, including ≈ $6.90 of net unfavorable items.
• Adjusted shareholders’ earnings: ≥ $26.75 per diluted share (excludes the ~$6.90 net unfavorable items).
• Benefit expense ratio guidance: 90.2% ± 50 basis points for full‑year 2026.

Why It Matters A reaffirmation of guidance provides investors with continued visibility into the company’s expected profitability and cost trends. The gap between the $19.85 shareholders’ earnings and the $26.75 adjusted figure reflects the impact of identified net unfavorable items—important when comparing reported results to the company’s adjusted operating view. The benefit expense ratio guidance (around 90%) signals management’s outlook on medical/benefit cost pressure, which is a key driver of margins for a health insurer.